BR112021022378A2 - Derivado de tetraidroisoquinolina substituído como um modulador alostérico d1 positivo - Google Patents

Derivado de tetraidroisoquinolina substituído como um modulador alostérico d1 positivo

Info

Publication number
BR112021022378A2
BR112021022378A2 BR112021022378A BR112021022378A BR112021022378A2 BR 112021022378 A2 BR112021022378 A2 BR 112021022378A2 BR 112021022378 A BR112021022378 A BR 112021022378A BR 112021022378 A BR112021022378 A BR 112021022378A BR 112021022378 A2 BR112021022378 A2 BR 112021022378A2
Authority
BR
Brazil
Prior art keywords
positive
allosteric modulator
tetrahydroisoquinoline derivative
substituted tetrahydroisoquinoline
derivative
Prior art date
Application number
BR112021022378A
Other languages
English (en)
Portuguese (pt)
Inventor
Ali Ates
David Skolc
Original Assignee
UCB Biopharma SRL
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by UCB Biopharma SRL filed Critical UCB Biopharma SRL
Publication of BR112021022378A2 publication Critical patent/BR112021022378A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/12—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with radicals, substituted by hetero atoms, attached to carbon atoms of the nitrogen-containing ring
    • C07D217/14—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with radicals, substituted by hetero atoms, attached to carbon atoms of the nitrogen-containing ring other than aralkyl radicals
    • C07D217/16—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with radicals, substituted by hetero atoms, attached to carbon atoms of the nitrogen-containing ring other than aralkyl radicals substituted by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
    • C07D261/20—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings condensed with carbocyclic rings or ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/07—Optical isomers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Neurosurgery (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Psychology (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Addiction (AREA)
  • Anesthesiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
BR112021022378A 2019-07-01 2020-06-29 Derivado de tetraidroisoquinolina substituído como um modulador alostérico d1 positivo BR112021022378A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP19183643 2019-07-01
PCT/EP2020/068183 WO2021001288A1 (en) 2019-07-01 2020-06-29 A substituted tetrahydroisoquinoline derivative as a d1 positive allosteric modulator

Publications (1)

Publication Number Publication Date
BR112021022378A2 true BR112021022378A2 (pt) 2022-03-08

Family

ID=67137843

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112021022378A BR112021022378A2 (pt) 2019-07-01 2020-06-29 Derivado de tetraidroisoquinolina substituído como um modulador alostérico d1 positivo

Country Status (23)

Country Link
US (1) US12643877B2 (cg-RX-API-DMAC7.html)
EP (1) EP3993794A1 (cg-RX-API-DMAC7.html)
JP (1) JP7510444B2 (cg-RX-API-DMAC7.html)
KR (1) KR20220029686A (cg-RX-API-DMAC7.html)
CN (2) CN117700395A (cg-RX-API-DMAC7.html)
AR (1) AR119318A1 (cg-RX-API-DMAC7.html)
AU (1) AU2020299953B2 (cg-RX-API-DMAC7.html)
BR (1) BR112021022378A2 (cg-RX-API-DMAC7.html)
CA (1) CA3139571A1 (cg-RX-API-DMAC7.html)
CL (1) CL2021002946A1 (cg-RX-API-DMAC7.html)
CO (1) CO2021018155A2 (cg-RX-API-DMAC7.html)
EC (1) ECSP21093559A (cg-RX-API-DMAC7.html)
IL (2) IL319939A (cg-RX-API-DMAC7.html)
MA (1) MA56440A (cg-RX-API-DMAC7.html)
MX (2) MX2021015873A (cg-RX-API-DMAC7.html)
MY (1) MY210361A (cg-RX-API-DMAC7.html)
PE (1) PE20221020A1 (cg-RX-API-DMAC7.html)
PH (1) PH12021552825A1 (cg-RX-API-DMAC7.html)
SA (1) SA521431279B1 (cg-RX-API-DMAC7.html)
SG (1) SG11202112537YA (cg-RX-API-DMAC7.html)
TW (1) TWI875776B (cg-RX-API-DMAC7.html)
WO (1) WO2021001288A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA202109193B (cg-RX-API-DMAC7.html)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020131671A1 (en) 2018-12-18 2020-06-25 Eli Lilly And Company Dose regimens for use of ly3154207 in the treatment of dopaminergic cns disorders
EP4200280B1 (en) 2020-10-07 2024-02-21 Eli Lilly And Company Phenyl-3,4-dihydroisoquinolin-2(1h)-yl-ethan-1-one derivatives as dopamine d1 receptor positive allosteric modulators
SI4263517T1 (sl) 2020-12-18 2025-01-31 UCB Biopharma SRL Substituiran tetrahidroizokinolinski derivat kot pozitivni alosterični modulator d1
CN116685308A (zh) 2020-12-18 2023-09-01 Ucb生物制药有限责任公司 无定形固体分散体
ES3004257T3 (en) 2020-12-18 2025-03-12 UCB Biopharma SRL Prodrugs of 2-(3,5-dichloro-1-methyl-indazol-4-yl)-1-[(1s,3r)-3-(hydroxymethyl)-5-(1-hydroxy-1-methyl-ethyl)-1-methyl-3,4-dihydro-1h-isoquinolin-2-yl]ethanone
CN117337173A (zh) * 2021-03-09 2024-01-02 伊莱利利公司 美维达林和其他d1正向别构调节剂用于减缓帕金森氏病进展的用途
WO2026022198A1 (en) 2024-07-25 2026-01-29 UCB Biopharma SRL Process for the preparation of 2-(3,5-dichloro-1-methyl-indazol-4-yl)-1-[(1 s,3 r)-3-(hydroxymethyl)-5-(1-hydroxy-1-methyl-ethyl)-1-methyl-3,4-dihydro-1 h-isoquinolin-2-yl]ethanone monohydrate

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2010520217A (ja) * 2007-03-01 2010-06-10 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ ヒスタミンh3受容体のモジュレーターとしてのテトラヒドロイソキノリン化合物
KR101284796B1 (ko) 2011-10-05 2013-07-10 (주)포인트엔지니어링 캔 패지키 타입의 광 디바이스 제조 방법 및 이에 의해 제조된 광 디바이스
US9278960B2 (en) 2011-11-03 2016-03-08 Merck Sharp & Dohme Corp. Quinoline carboxamide and quinoline carbonitrile derivatives as mGluR2-negative allosteric modulators, compositions, and their use
JO3316B1 (ar) 2013-05-30 2019-03-13 Lilly Co Eli مركبات 3، 4-داي هيدرو أيزو كوينولين -2(1h)-يل
EA035544B1 (ru) 2014-10-08 2020-07-03 Юсб Байофарма Спрл Производные тетрагидроизохинолина
CN108884050B (zh) * 2016-04-13 2022-07-05 Ucb生物制药私人有限公司 四氢异喹啉衍生物
TWI725408B (zh) 2018-04-20 2021-04-21 美商美國禮來大藥廠 多巴胺d1受體正向異位調節劑

Also Published As

Publication number Publication date
SG11202112537YA (en) 2021-12-30
WO2021001288A9 (en) 2021-09-02
AU2020299953B2 (en) 2025-06-05
TWI875776B (zh) 2025-03-11
IL289314A (en) 2022-02-01
PH12021552825A1 (en) 2022-10-03
US12643877B2 (en) 2026-06-02
ZA202109193B (en) 2023-11-29
AU2020299953A1 (en) 2022-01-06
CN113993857A (zh) 2022-01-28
MX2021015873A (es) 2022-02-03
TW202537959A (zh) 2025-10-01
SA521431279B1 (ar) 2024-01-09
MX2024015493A (es) 2025-02-10
IL319939A (en) 2025-05-01
IL289314B2 (en) 2025-09-01
TW202115010A (zh) 2021-04-16
US20220259179A1 (en) 2022-08-18
CN117700395A (zh) 2024-03-15
MA56440A (fr) 2022-05-11
CL2021002946A1 (es) 2022-07-15
KR20220029686A (ko) 2022-03-08
CN113993857B (zh) 2024-01-02
IL289314B1 (en) 2025-05-01
JP7510444B2 (ja) 2024-07-03
ECSP21093559A (es) 2022-02-25
PE20221020A1 (es) 2022-06-16
CA3139571A1 (en) 2021-01-07
WO2021001288A1 (en) 2021-01-07
MY210361A (en) 2025-09-13
AR119318A1 (es) 2021-12-09
JP2022539152A (ja) 2022-09-07
CO2021018155A2 (es) 2022-01-17
EP3993794A1 (en) 2022-05-11

Similar Documents

Publication Publication Date Title
MX2024015493A (es) Un derivado de tetrahidroisoquinolina sustituido como modulador alosterico positivo de d1
BR112017007123A2 (pt) derivados de tetrahidroisoquinolina
BR112015031903A2 (pt) composto, sal farmaceuticamente aceitável do composto, composição farmacêutica e utilização de um composto
BR112015022096A2 (pt) moduladores de canal de sódio para o tratamento da dor
BR112017008312A2 (pt) novos compostos de piridopirimidinona para modular a atividade catalítica de histona lisina demetilases (kdms)
BR112015023142A2 (pt) moduladores de p2x7
BR112017010188A2 (pt) análogos de éter fosfolipídeos como veículos de fármacos alvejando câncer
BR112015022566A2 (pt) composto e composição farmacêutica
BR112015032623A8 (pt) composto, composição farmacêutica, combinação, e, uso de um composto
BR112015023948A2 (pt) composto de fórmula (i), composição farmacêutica, método para o tratamento e/ou prevenção de uma doença proliferativa e para a inibição ou a diferenciação do crescimento de uma célula tronco do câncer
BR112022006507A2 (pt) Compostos heterocíclicos de arilmetileno como bloqueadores de canais de agitador de potássio kv1.3
BR112015011031A2 (pt) moduladores de grp40 de di-hidropirazol
BR112019021867A2 (pt) Compostos de fenil-2-hidroxi-acetilamino-2-metil-fenil
BR112015022092A2 (pt) derivado de di-hidropiridazina-3,5-diona
BR112021022379A2 (pt) Derivado de tetraidroisoquinolina substituído como um modulador alosterico d1 positivo
BR112016006970A2 (pt) enzalutamida em combinação com afuresertib para o tratamento de câncer
BR112015022290A2 (pt) derivados de heterocíclicos benzo-fundidos úteis como agonistas de gpr120
BR112015026512A2 (pt) composto acetamida heterocíclico
BR112017015597A2 (pt) moduladores dos receptores da adenosina a3
BR112022006226A2 (pt) Compostos heterocíclicos de arilmetileno como bloqueadores de canal do agitador de potássio kv1,3
ECSP23041779A (es) Un derivado de tetrahidroisoquinolina sustituido como un modulador alostérico positivo de d1
BR112021016912A2 (pt) Composto de benzoindazolona e intermediário do mesmo
BR112019024892A2 (pt) Derivados de piridoquinazolina úteis como inibidores de proteína quinase
BR112018067789A2 (pt) análogos de nucleosídeos substituídos para uso como inibidores de prmt5
BR112017002217A2 (pt) composto da fórmula (i), composição farmacêutica, e usos de um composto

Legal Events

Date Code Title Description
B06W Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette]